{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:03:31Z","timestamp":1786982611198,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":173,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K07120"],"award-info":[{"award-number":["JP19K07120"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP17K08360"],"award-info":[{"award-number":["JP17K08360"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19H01014"],"award-info":[{"award-number":["JP19H01014"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"name":"YOKOYAMA Foundation for Clinical Pharmacology","award":["YRY-1903"],"award-info":[{"award-number":["YRY-1903"]}]},{"name":"Hokkoku Cancer Foundation"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21gm0910012h0004"],"award-info":[{"award-number":["21gm0910012h0004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s13311-022-01337-1","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T11:05:47Z","timestamp":1673262347000},"page":"484-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Intranasal Administration of Resolvin E1 Produces Antidepressant-Like Effects via BDNF\/VEGF-mTORC1 Signaling in the Medial Prefrontal Cortex"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5502-9746","authenticated-orcid":false,"given":"Satoshi","family":"Deyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinako","family":"Sugie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masabumi","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-022-01337-1_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4088\/JCP.14m09298","article-title":"The economic burden of adults with major depressive disorder in the United States (2005 and 2010)","volume":"76","author":"Greenberg","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression\u2014first FDA-approved antidepressant in a new class","volume":"381","author":"Kim","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01337-1_bib6","doi-asserted-by":"crossref","first-page":"l7069","DOI":"10.1136\/bmj.l7069","article-title":"Esketamine is approved in Europe for treating resistant major depressive disorder","volume":"367","author":"Mahase","year":"2019","journal-title":"BMJ"},{"key":"10.1007\/s13311-022-01337-1_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib9","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib10","doi-asserted-by":"crossref","first-page":"172837","DOI":"10.1016\/j.pbb.2019.172837","article-title":"Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine","volume":"188","author":"Deyama","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1007\/s13311-022-01337-1_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ejn.14630","article-title":"Role of BDNF in the pathophysiology and treatment of depression: activity-dependent effects distinguish rapid-acting antidepressants","volume":"53","author":"Duman","year":"2021","journal-title":"Eur J Neurosci"},{"key":"10.1007\/s13311-022-01337-1_bib12","doi-asserted-by":"crossref","first-page":"109335","DOI":"10.1016\/j.neuropharm.2022.109335","article-title":"Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine","volume":"224","author":"Deyama","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-022-01337-1_bib13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1007\/s13311-022-01337-1_bib14","doi-asserted-by":"crossref","first-page":"pyu033","DOI":"10.1093\/ijnp\/pyu033","article-title":"BDNF release is required for the behavioral actions of ketamine","volume":"18","author":"Lepack","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1007\/s13311-022-01337-1_bib15","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/mp.2017.220","article-title":"BDNF release and signaling are required for the antidepressant actions of GLYX-13","volume":"23","author":"Kato","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.biopsych.2017.06.017","article-title":"Activity-dependent brain-derived neurotrophic factor release is required for the rapid antidepressant actions of scopolamine","volume":"83","author":"Ghosal","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/npp.2016.202","article-title":"GLYX-13 produces rapid antidepressant responses with key synaptic and behavioral effects distinct from ketamine","volume":"42","author":"Liu","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-022-01337-1_bib18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.biopsych.2013.04.025","article-title":"Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses","volume":"74","author":"Voleti","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuropharm.2016.09.011","article-title":"Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures","volume":"111","author":"Lepack","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-022-01337-1_bib20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1176\/appi.ajp.2018.17121368","article-title":"Role of neuronal VEGF signaling in the prefrontal cortex in the rapid antidepressant effects of ketamine","volume":"176","author":"Deyama","year":"2019","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.biopsych.2018.12.014","article-title":"Neurotrophic and antidepressant actions of brain-derived neurotrophic factor require vascular endothelial growth factor","volume":"86","author":"Deyama","year":"2019","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbadis.2016.04.001","article-title":"Hippocampal VEGF is necessary for antidepressant-like behaviors but not sufficient for antidepressant-like effects of ketamine in rats","volume":"1862","author":"Choi","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1007\/s13311-022-01337-1_bib23","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/s41467-017-01709-8","article-title":"TrkB dependent adult hippocampal progenitor differentiation mediates sustained ketamine antidepressant response","volume":"8","author":"Ma","year":"2017","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-022-01337-1_bib24","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cellsig.2007.12.009","article-title":"Vascular endothelial growth factor (VEGF) signaling regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium\/calmodulin protein kinase II and mammalian target of rapamycin","volume":"20","author":"Kim","year":"2008","journal-title":"Cell Signal"},{"key":"10.1007\/s13311-022-01337-1_bib25","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bph.14336","article-title":"Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology","volume":"176","author":"Dalli","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1007\/s13311-022-01337-1_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri2294","article-title":"Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators","volume":"8","author":"Serhan","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1007\/s13311-022-01337-1_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jphs.2021.05.002","article-title":"Resolvins as potential candidates for the treatment of major depressive disorder","volume":"147","author":"Deyama","year":"2021","journal-title":"J Pharmacol Sci"},{"key":"10.1007\/s13311-022-01337-1_bib28","doi-asserted-by":"crossref","unstructured":"Deyama S, Kaneda K, Minami M. Resolution of depression: antidepressant actions of resolvins. Neurosci Res. in press. https:\/\/doi.org\/10.1016\/j.neures.2022.10.006.","DOI":"10.1016\/j.neures.2022.10.006"},{"key":"10.1007\/s13311-022-01337-1_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00213-017-4774-7","article-title":"Resolvin E1\/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23","volume":"235","author":"Deyama","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1007\/s13311-022-01337-1_bib30","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1248\/bpb.b21-00461","article-title":"Resolvin E1 attenuates chronic pain-induced depression-like behavior in mice: possible involvement of chemerin receptor ChemR23","volume":"44","author":"Suzuki","year":"2021","journal-title":"Biol Pharm Bull"},{"key":"10.1007\/s13311-022-01337-1_bib31","doi-asserted-by":"crossref","first-page":"113676","DOI":"10.1016\/j.bbr.2021.113676","article-title":"The antidepressant effect of resolvin E1 in repeated prednisolone-induced depression model mice","volume":"418","author":"Aoki","year":"2022","journal-title":"Behav Brain Res"},{"key":"10.1007\/s13311-022-01337-1_bib32","doi-asserted-by":"crossref","first-page":"22847","DOI":"10.1074\/jbc.M603766200","article-title":"Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions","volume":"281","author":"Arita","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-022-01337-1_bib33","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2174\/1570159X11311060009","article-title":"Resolvins: Endogenously-generated potent painkilling substances and their therapeutic perspectives","volume":"11","author":"Yoo","year":"2013","journal-title":"Curr Neuropharmacol"},{"key":"10.1007\/s13311-022-01337-1_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10717544.2013.838713","article-title":"Insights into direct nose to brain delivery: current status and future perspective","volume":"21","author":"Mittal","year":"2014","journal-title":"Drug Deliv"},{"key":"10.1007\/s13311-022-01337-1_bib35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1021\/acsmedchemlett.0c00639","article-title":"Synthesis of resolvin E1 and its conformationally restricted cyclopropane congeners with potent anti-inflammatory effect","volume":"12","author":"Ishimura","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1007\/s13311-022-01337-1_bib36","series-title":"The mouse brain in stereotaxic coordinates","author":"Franklin","year":"2007"},{"key":"10.1007\/s13311-022-01337-1_bib37","doi-asserted-by":"crossref","first-page":"112844","DOI":"10.1016\/j.bbr.2020.112844","article-title":"The duration of the antidepressant-like effects of a single infusion of brain-derived neurotrophic factor into the medial prefrontal cortex in mice","volume":"394","author":"Deyama","year":"2020","journal-title":"Behav Brain Res"},{"key":"10.1007\/s13311-022-01337-1_bib38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41398-022-01943-9","article-title":"IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine","volume":"12","author":"Deyama","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neuropharm.2018.05.001","article-title":"5-HT1A receptor stimulation in the medial prefrontal cortex mediates the antidepressant effects of mGlu2\/3 receptor antagonist in mice","volume":"137","author":"Fukumoto","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-022-01337-1_bib40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/ijnp\/pyx023","article-title":"Resolvin D1 and D2 reverse lipopolysaccharide-induced depression-like behaviors through the mTORC1 signaling pathway","volume":"20","author":"Deyama","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1007\/s13311-022-01337-1_bib41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jphs.2018.09.006","article-title":"Resolvin E3 attenuates lipopolysaccharide-induced depression-like behavior in mice","volume":"138","author":"Deyama","year":"2018","journal-title":"J Pharmacol Sci"},{"key":"10.1007\/s13311-022-01337-1_bib42","first-page":"243","article-title":"Prednisolone causes anxiety- and depression-like behaviors and altered expression of apoptotic genes in mice hippocampus","volume":"54","author":"Kajiyama","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib43","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s00213-019-05222-2","article-title":"Effects of the synthetic cannabinoid 5F-AMB on anxiety and recognition memory in mice","volume":"236","author":"Ito","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1007\/s13311-022-01337-1_bib44","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/npp.2012.246","article-title":"GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects","volume":"38","author":"Burgdorf","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-022-01337-1_bib45","doi-asserted-by":"crossref","first-page":"20615","DOI":"10.1074\/jbc.M114.568659","article-title":"Rapamycin and interleukin-1beta impair brain-derived neurotrophic factor-dependent neuron survival by modulating autophagy","volume":"289","author":"Smith","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-022-01337-1_bib46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.103.063222","article-title":"Brain uptake of the glucagon-like peptide-1 antagonist exendin(9\u201339) after intranasal administraion","volume":"309","author":"Banks","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-022-01337-1_bib47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejphar.2010.05.033","article-title":"Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration","volume":"641","author":"Ducharme","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-022-01337-1_bib48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","article-title":"Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration","volume":"452","author":"Yang","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1007\/s13311-022-01337-1_bib49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.peptides.2016.11.013","article-title":"Antidepressant-like effects exerted by the intranasal administration of a glucagon-like peptide-2 derivative containing cell-penetrating peptides and a penetration-accelerating sequence in mice","volume":"87","author":"Sasaki-Hamada","year":"2017","journal-title":"Peptides"},{"key":"10.1007\/s13311-022-01337-1_bib50","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1021\/acs.molpharmaceut.0c00170","article-title":"Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes","volume":"17","author":"Dhaliwal","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1007\/s13311-022-01337-1_bib51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1007\/s13311-022-01337-1_bib52","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.psyneuen.2007.03.005","article-title":"Lipopolysaccharide induces delayed FosB\/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior","volume":"32","author":"Frenois","year":"2007","journal-title":"Psychoneuroendocrinology"},{"key":"10.1007\/s13311-022-01337-1_bib53","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1038\/s41386-018-0154-1","article-title":"Resolution of inflammation-induced depression requires T lymphocytes and endogenous brain interleukin-10 signaling","volume":"43","author":"Laumet","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-022-01337-1_bib54","unstructured":"World Health Organization. Depression fact sheets. 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression\/. Accessed 25 Apr 2022."},{"key":"10.1007\/s13311-022-01337-1_bib55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuroscience.2018.12.008","article-title":"The sex-specific effects of LPS on depressive-like behavior and oxidative stress in the hippocampus of the mouse","volume":"399","author":"Millett","year":"2019","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-022-01337-1_bib56","doi-asserted-by":"crossref","first-page":"105097","DOI":"10.1016\/j.neuint.2021.105097","article-title":"Lipopolysaccharide-induced depression is associated with estrogen receptor-alpha\/SIRT1\/NF-kappaB signaling pathway in old female mice","volume":"148","author":"Jiang","year":"2021","journal-title":"Neurochem Int"},{"key":"10.1007\/s13311-022-01337-1_bib57","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0022-3999(00)00187-2","article-title":"Exogenous corticosteroids and major depression in the general population","volume":"49","author":"Patten","year":"2000","journal-title":"J Psychosom Res"},{"key":"10.1007\/s13311-022-01337-1_bib58","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-022-01337-1_bib59","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1172\/JCI85033","article-title":"GABA interneurons mediate the rapid antidepressant-like effects of scopolamine","volume":"126","author":"Wohleb","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-022-01337-1_bib60","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1172\/JCI130808","article-title":"GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions","volume":"130","author":"Gerhard","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-022-01337-1_bib61","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-022-01337-1_bib62","doi-asserted-by":"crossref","first-page":"8688","DOI":"10.1523\/JNEUROSCI.6078-08.2009","article-title":"Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation","volume":"29","author":"Jourdi","year":"2009","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-022-01337-1_bib63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01337-1_bib64","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41386-020-0644-9","article-title":"Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin","volume":"45","author":"Abdallah","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-022-01337-1_bib65","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1172\/JCI126859","article-title":"Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation","volume":"129","author":"Kato","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-022-01337-1_bib66","unstructured":"Navitor. Navitor's three phase 1 studies for NV-5138 show antidepressant effects and biomarker impact, supporting further development of direct activator of mTORC1 in depression. 2019. http:\/\/www.navitorpharma.com\/navitors-three-phase-1-studies-for-nv-5138-show-antidepressant-effects-and-biomarker-impact-supporting-further-development-of-direct-activator-of-mtorc1-in-depression\/. Accessed 25 Apr 2022."},{"key":"10.1007\/s13311-022-01337-1_bib67","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/pr.116.013177","article-title":"International union of basic and clinical pharmacology CIII: chemerin receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) nomenclature, pharmacology, and function","volume":"70","author":"Kennedy","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1007\/s13311-022-01337-1_bib68","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bpa.12812","article-title":"Receptors for pro-resolving mediators are increased in Alzheimer's disease brain","volume":"30","author":"Emre","year":"2020","journal-title":"Brain Pathol"},{"key":"10.1007\/s13311-022-01337-1_bib69","doi-asserted-by":"crossref","first-page":"107710","DOI":"10.1016\/j.neuropharm.2019.107710","article-title":"Potential link between antidepressant-like effects of ketamine and promotion of adult neurogenesis in the ventral hippocampus of mice","volume":"158","author":"Yamada","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-022-01337-1_bib70","doi-asserted-by":"crossref","first-page":"113625","DOI":"10.1016\/j.bbr.2021.113625","article-title":"GluN2A-ERK-mTOR pathway confers a vulnerability to LPS-induced depression-like behaviour","volume":"417","author":"Francija","year":"2022","journal-title":"Behav Brain Res"},{"key":"10.1007\/s13311-022-01337-1_bib71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12974-019-1610-5","article-title":"Potential link between the RagA-mTOR-p70S6K axis and depressive-behaviors during bacterial liposaccharide challenge","volume":"16","author":"Zhao","year":"2019","journal-title":"J Neuroinflammation"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01337-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923000934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923000934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:34:10Z","timestamp":1761806050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923000934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1878747923000934"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01337-1","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal Administration of Resolvin E1 Produces Antidepressant-Like Effects via BDNF\/VEGF-mTORC1 Signaling in the Medial Prefrontal Cortex","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01337-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}